Literature DB >> 23183899

Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS.

Rafaela Martin1, Jennifer Schürenkamp, Angela Gasse, Heidi Pfeiffer, Helga Köhler.   

Abstract

A validated method for the simultaneous determination of psilocin, bufotenine, lysergic acid diethylamide and its metabolites in serum, plasma and urine using liquid chromatography-electrospray ionization/tandem mass spectrometry was developed. During the solid-phase extraction procedure with polymeric mixed-mode cation exchange columns, the unstable analytes were protected by ascorbic acid, drying with nitrogen and exclusion of light. The limits of detection and quantitation for all analytes were low. Recovery was ≥86 % for all analytes and no significant matrix effects were observed. Interday and intraday imprecisions at different concentrations ranged from 1.1 to 8.2 % relative standard deviation, bias was within ±5.3 %. Processed samples were stable in the autosampler for at least 2 days. Furthermore, freeze/thaw and long-term stability were investigated. The method was successfully applied to authentic serum and urine samples.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183899     DOI: 10.1007/s00414-012-0796-1

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  28 in total

Review 1.  Recent advances in chromatographic and mass spectrometric methods for determination of LSD and its metabolites in physiological specimens.

Authors:  S A Reuschel; D Eades; R L Foltz
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-10-15

2.  Short-term stability of lysergic acid diethylamide (LSD), N-desmethyl-LSD, and 2-oxo-3-hydroxy-LSD in urine, assessed by liquid chromatography-tandem mass spectrometry.

Authors:  Gisela Skopp; Lucia Pötsch; Rainer Mattern; Rolf Aderjan
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

3.  The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates.

Authors:  A HORITA; L J WEBER
Journal:  Biochem Pharmacol       Date:  1961-07       Impact factor: 5.858

4.  A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability.

Authors:  Rafaela Martin; Jennifer Schürenkamp; Heidi Pfeiffer; Helga Köhler
Journal:  Int J Legal Med       Date:  2011-12-03       Impact factor: 2.686

5.  Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues.

Authors:  J Kärkkäinen; T Forsström; J Tornaeus; K Wähälä; P Kiuru; A Honkanen; U H Stenman; U Turpeinen; A Hesso
Journal:  Scand J Clin Lab Invest       Date:  2005       Impact factor: 1.713

6.  The presence of free and conjugated bufotenin in normal human urine.

Authors:  M J Räisänen
Journal:  Life Sci       Date:  1984-05-21       Impact factor: 5.037

7.  The detection of psilocin in human urine.

Authors:  A F Grieshaber; K A Moore; B Levine
Journal:  J Forensic Sci       Date:  2001-05       Impact factor: 1.832

8.  Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS.

Authors:  T Forsström; J Tuominen; J Karkkäinen
Journal:  Scand J Clin Lab Invest       Date:  2001       Impact factor: 1.713

9.  Validated ultra-performance liquid chromatography-tandem mass spectrometry method for analyzing LSD, iso-LSD, nor-LSD, and O-H-LSD in blood and urine.

Authors:  Angela Chung; John Hudson; Gordon McKay
Journal:  J Anal Toxicol       Date:  2009-06       Impact factor: 3.367

10.  Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry.

Authors:  D I Papac; R L Foltz
Journal:  J Anal Toxicol       Date:  1990 May-Jun       Impact factor: 3.367

View more
  8 in total

1.  Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects.

Authors:  Friederike Holze; Urs Duthaler; Patrick Vizeli; Felix Müller; Stefan Borgwardt; Matthias E Liechti
Journal:  Br J Clin Pharmacol       Date:  2019-04-29       Impact factor: 4.335

2.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

3.  Optimization through a Box-Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi (Psylocibe cubensis).

Authors:  Curro Polo-Castellano; José Á Álvarez; Miguel Palma; Gerardo F Barbero; Jesús Ayuso; Marta Ferreiro-González
Journal:  J Fungi (Basel)       Date:  2022-06-02

4.  Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.

Authors:  Patrick C Dolder; Yasmin Schmid; Manuel Haschke; Katharina M Rentsch; Matthias E Liechti
Journal:  Int J Neuropsychopharmacol       Date:  2015-06-24       Impact factor: 5.176

5.  Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.

Authors:  Patrick C Dolder; Yasmin Schmid; Andrea E Steuer; Thomas Kraemer; Katharina M Rentsch; Felix Hammann; Matthias E Liechti
Journal:  Clin Pharmacokinet       Date:  2017-10       Impact factor: 6.447

Review 6.  Toxicology and Analysis of Psychoactive Tryptamines.

Authors:  Sara Malaca; Alfredo Fabrizio Lo Faro; Alice Tamborra; Simona Pichini; Francesco Paolo Busardò; Marilyn A Huestis
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

Review 7.  Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Authors:  Maurizio Coppola; Francesco Bevione; Raffaella Mondola
Journal:  J Xenobiot       Date:  2022-02-07

8.  Direct Analysis of Psilocin and Muscimol in Urine Samples Using Single Drop Microextraction Technique In-Line with Capillary Electrophoresis.

Authors:  Anna Poliwoda; Katarzyna Zielińska; Piotr P Wieczorek
Journal:  Molecules       Date:  2020-03-29       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.